{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:40:25Z","timestamp":1759488025370,"version":"build-2065373602"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["11180825","3210294","1220573"],"award-info":[{"award-number":["11180825","3210294","1220573"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018735","name":"Fondo de Financiamiento de Centros de Investigaci\u00f3n en \u00c1reas Prioritarias","doi-asserted-by":"publisher","award":["15150012"],"award-info":[{"award-number":["15150012"]}],"id":[{"id":"10.13039\/501100018735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["ID1ID22I10120"],"award-info":[{"award-number":["ID1ID22I10120"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000181","name":"U.S. Air Force Office of Scientific Research","doi-asserted-by":"crossref","award":["FA9550-21-1-0096"],"award-info":[{"award-number":["FA9550-21-1-0096"]}],"id":[{"id":"10.13039\/100000181","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110960"],"award-info":[{"award-number":["W81XWH2110960"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium Institute","award":["P09-015-F"],"award-info":[{"award-number":["P09-015-F"]}]},{"name":"Swiss Consolidation Grant","award":["The Leading House for the Latin American Region"],"award-info":[{"award-number":["The Leading House for the Latin American Region"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>High-grade astrocytomas vary in incidence and mortality across populations, with Hispanic and Latino groups largely underrepresented in genomic epidemiology studies. This study characterizes the presence of known mutations of high-grade astrocytomas in a Latin American cohort through targeted genomic analysis of 70 Chilean patients. Molecular markers, including <jats:italic>IDH<\/jats:italic>, <jats:italic>TERTp<\/jats:italic>, <jats:italic>H3<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>PTEN<\/jats:italic>, <jats:italic>EGFR<\/jats:italic>, and <jats:italic>CDKN2A<\/jats:italic>, were assessed alongside survival analyses. Our results mostly aligned with international cohorts, confirming the importance of established molecular markers in glioblastoma. Novel damaging <jats:italic>TP53<\/jats:italic> and <jats:italic>PTEN<\/jats:italic> mutations were identified, expanding the genetic spectrum of known mutations for these genes, while a lower-than-expected <jats:italic>NF1<\/jats:italic> mutation frequency was observed (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). These findings highlight the importance of examining underrepresented populations, providing insights into the molecular characteristics of high-grade astrocytomas in Latin America. Our findings contribute to understanding the diversity of genomic features across astrocytoma populations, setting a foundation for future international comparative studies.<\/jats:p>","DOI":"10.1038\/s41598-025-06129-z","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:02:33Z","timestamp":1759485753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Rodrigo","family":"Fern\u00e1ndez-Gajardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hery","family":"Urra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Pih\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Sanchez-Do\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Cavada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Tissera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3mulo","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rojas-Zalazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Matamala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Hetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"6129_CR1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The Cancer genome atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"6129_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112\u2013120 (2019).","journal-title":"Nature"},{"key":"6129_CR3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel, R. A. et al. Genomic and phenotypic characterization of a broad panel of Patient-Derived xenografts reflects the diversity of glioblastoma. Clin. Cancer Res. 26, 1094\u20131104 (2020).","journal-title":"Clin. Cancer Res."},{"key":"6129_CR4","doi-asserted-by":"publisher","first-page":"7352","DOI":"10.1002\/cam4.3370","volume":"9","author":"H Koo","year":"2020","unstructured":"Koo, H. et al. Ethnic delineation of primary glioblastoma genome. Cancer Med. 9, 7352\u20137359 (2020).","journal-title":"Cancer Med."},{"key":"6129_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550\u2013563 (2016).","journal-title":"Cell"},{"key":"6129_CR6","doi-asserted-by":"crossref","unstructured":"Chac\u00f3n-Duque, J. C. et al. Latin Americans show wide-spread Converso ancestry and imprint of local Native ancestry on physical appearance. Nature Communications 2018 9:1 9, 1\u201313 (2018).","DOI":"10.1038\/s41467-018-07748-z"},{"key":"6129_CR7","doi-asserted-by":"crossref","unstructured":"Ruiz-Linares, A. et al. Admixture in Latin america: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet 10, (2014).","DOI":"10.1371\/journal.pgen.1004572"},{"key":"6129_CR8","doi-asserted-by":"crossref","unstructured":"Eyheramendy, S., Martinez, F. I., Manevy, F., Vial, C. & Repetto, G. M. Genetic structure characterization of Chileans reflects historical immigration patterns. Nature Communications 2015 6:1 6, 1\u201310 (2015).","DOI":"10.1038\/ncomms7472"},{"key":"6129_CR9","doi-asserted-by":"crossref","unstructured":"Verdugo, R. A. et al. Development of a small panel of SNPs to infer ancestry in Chileans that distinguishes Aymara and Mapuche components. Biol Res 53, (2020).","DOI":"10.1186\/s40659-020-00284-5"},{"key":"6129_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4067\/S0034-98872002000200001","volume":"130","author":"P Rocco","year":"2002","unstructured":"Rocco, P. Composici\u00f3n gen\u00e9tica de La Poblaci\u00f3n chilena. Distribuci\u00f3n de Polimorfismos de DNA mitocondrial En grupos originarios y En La Poblaci\u00f3n Mixta de Santiago. Rev. Med. Chil. 130, 125\u2013131 (2002).","journal-title":"Rev. Med. Chil."},{"key":"6129_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1590\/1678-4685-gmb-2015-0273","volume":"39","author":"CD Vieira-Machado","year":"2016","unstructured":"Vieira-Machado, C. D. et al. Uniparental ancestry markers in Chilean populations. Genet. Mol. Biol. 39, 573\u2013579 (2016).","journal-title":"Genet. Mol. Biol."},{"key":"6129_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/neuonc\/noad100","volume":"25","author":"F Sahm","year":"2023","unstructured":"Sahm, F. et al. Molecular diagnostic tools for the world health organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol. 25, 1731\u20131749 (2023).","journal-title":"Neuro Oncol."},{"key":"6129_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"6129_CR14","doi-asserted-by":"crossref","unstructured":"Horbinski, C., Berger, T., Packer, R. J. & Wen, P. Y. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nature Reviews Neurology 2022 18:9 18, 515\u2013529 (2022).","DOI":"10.1038\/s41582-022-00679-w"},{"key":"6129_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","volume":"8","author":"TR Berger","year":"2022","unstructured":"Berger, T. R., Wen, P. Y., Lang-Orsini, M. & Chukwueke, U. N. World health organization 2021 classification of central nervous system tumors and implications for therapy for Adult-Type gliomas: A review. JAMA Oncol. 8, 1493\u20131501 (2022).","journal-title":"JAMA Oncol."},{"key":"6129_CR16","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1148\/rg.210236","volume":"42","author":"R Kurokawa","year":"2022","unstructured":"Kurokawa, R. et al. Major changes in 2021 world health organization classification of central Nerus system tumors. Radiographics 42, 1474\u20131493 (2022).","journal-title":"Radiographics"},{"key":"6129_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cncr.33918","volume":"128","author":"S Gritsch","year":"2022","unstructured":"Gritsch, S., Batchelor, T. T. & Gonzalez Castro, L. N. Diagnostic, therapeutic, and prognostic implications of the 2021 world health organization classification of tumors of the central nervous system. Cancer 128, 47\u201358 (2022).","journal-title":"Cancer"},{"key":"6129_CR18","doi-asserted-by":"crossref","unstructured":"Eyheramendy, S., Martinez, F. I., Manevy, F., Vial, C. & Repetto, G. M. Genetic structure characterization of Chileans reflects historical immigration patterns. Nat Commun 6, (2015).","DOI":"10.1038\/ncomms7472"},{"key":"6129_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fonc.2019.00851","volume":"9","author":"A Petrackova","year":"2019","unstructured":"Petrackova, A. et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in Cancer diagnostics. Front. Oncol. 9, 851 (2019).","journal-title":"Front. Oncol."},{"key":"6129_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N Engl. J. Med. 360, 765 (2009).","journal-title":"N Engl. J. Med."},{"key":"6129_CR21","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.18632\/oncotarget.1765","volume":"5","author":"PJ Killela","year":"2014","unstructured":"Killela, P. J. et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5, 1515 (2014).","journal-title":"Oncotarget"},{"key":"6129_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel, D. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic Pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130, 815\u2013827 (2015).","journal-title":"Acta Neuropathol."},{"key":"6129_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226\u2013231 (2012).","journal-title":"Nature"},{"key":"6129_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 22, 425\u2013437 (2012).","journal-title":"Cancer Cell."},{"key":"6129_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","volume":"133","author":"M Pekmezci","year":"2017","unstructured":"Pekmezci, M. et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 133, 1001\u20131016 (2017).","journal-title":"Acta Neuropathol."},{"key":"6129_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/nou158","volume":"17","author":"M Simon","year":"2015","unstructured":"Simon, M. et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 17, 45\u201352 (2015).","journal-title":"Neuro Oncol."},{"key":"6129_CR27","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/bjc.2014.538","volume":"111","author":"M Labussi\u00e8re","year":"2014","unstructured":"Labussi\u00e8re, M. et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br. J. Cancer. 111, 2024\u20132032 (2014).","journal-title":"Br. J. Cancer"},{"key":"6129_CR28","first-page":"394","volume":"19","author":"HN Nguyen","year":"2017","unstructured":"Nguyen, H. N. et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. 19, 394\u2013404 (2017).","journal-title":"Neuro Oncol."},{"key":"6129_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay, R. et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 21, 1519 (2019).","journal-title":"Neuro Oncol."},{"key":"6129_CR30","first-page":"462","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. Somatic Genomic Landsc. Glioblastoma Cell 155, 462\u2013477 (2013).","journal-title":"Somatic Genomic Landsc. Glioblastoma Cell"},{"key":"6129_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2019","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer. 20, 74\u201388 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"6129_CR32","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero, L. J. & El-Deiry, W. S. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim. Et Biophys. Acta (BBA) - Reviews Cancer. 1876, 188556 (2021).","journal-title":"Biochim. Et Biophys. Acta (BBA) - Reviews Cancer"},{"key":"6129_CR33","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"6129_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data. Cancer Discov. 2, 401 (2012).","journal-title":"Cancer Discov"},{"key":"6129_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/neuonc\/noad022","volume":"25","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells. Neuro Oncol. 25, 1563\u20131575 (2023).","journal-title":"Neuro Oncol."},{"key":"6129_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14728222.2018.1487953","volume":"22","author":"S Haase","year":"2018","unstructured":"Haase, S. et al. Mutant ATRX: Uncovering a new therapeutic target for glioma. Expert Opin. Ther. Targets. 22, 599 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"6129_CR37","doi-asserted-by":"crossref","unstructured":"Diplas, B. H. et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun 9, (2018).","DOI":"10.1038\/s41467-018-04448-6"},{"key":"6129_CR38","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-19-0032","volume":"25","author":"P Jonsson","year":"2019","unstructured":"Jonsson, P. et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin. Cancer Res. 25, 5537\u20135547 (2019).","journal-title":"Clin. Cancer Res."},{"key":"6129_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-99278-w","volume":"11","author":"SN McNulty","year":"2021","unstructured":"McNulty, S. N. et al. BRAF mutations May identify a clinically distinct subset of glioblastoma. Sci. Rep. 11, 1\u201310 (2021).","journal-title":"Sci. Rep."},{"key":"6129_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1006402614838","volume":"48","author":"JA Kraus","year":"2000","unstructured":"Kraus, J. A. et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol. 48, 89\u201394 (2000).","journal-title":"J. Neurooncol"},{"key":"6129_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/01616412.2019.1638018","volume":"41","author":"NP Patel","year":"2019","unstructured":"Patel, N. P., Lyon, K. A. & Huang, J. H. The effect of race on the prognosis of the glioblastoma patient: a brief review. Neurol. Res. 41, 967\u2013971 (2019).","journal-title":"Neurol. Res."},{"key":"6129_CR42","doi-asserted-by":"publisher","unstructured":"Raez, L. E., Cardona, A. F., Arrieta, O. & Lopes, G. Lung Cancer disparities in hispanics: molecular diagnosis and use of immunotherapy. JCO Glob Oncol. 784\u2013788. https:\/\/doi.org\/10.1200\/go.20.00004 (2020).","DOI":"10.1200\/go.20.00004"},{"key":"6129_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-32264-x","volume":"8","author":"S Guerrero","year":"2018","unstructured":"Guerrero, S. et al. Analysis of racial\/ethnic representation in select basic and applied Cancer research studies. Sci. Rep. 8, 1\u20138 (2018).","journal-title":"Sci. Rep."},{"key":"6129_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/neuonc\/noac175","volume":"25","author":"KM Walsh","year":"2023","unstructured":"Walsh, K. M. et al. Influence of county-level geographic\/ancestral origin on glioma incidence and outcomes in US Hispanics. Neuro Oncol. 25, 398\u2013406 (2023).","journal-title":"Neuro Oncol."},{"key":"6129_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","volume":"13","author":"SP Strom","year":"2016","unstructured":"Strom, S. P. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol. Med. 13, 3 (2016).","journal-title":"Cancer Biol. Med."},{"key":"6129_CR46","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","volume":"23","author":"S Brandner","year":"2021","unstructured":"Brandner, S. et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane systematic review. Neuro Oncol. 23, 1457\u20131469 (2021).","journal-title":"Neuro Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06129-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:02:39Z","timestamp":1759485759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06129-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6129"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06129-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34485"}}